Coronado Industries Edges Closer toward Marketing Their PNT Glaucoma Treatment in China.

Beijing Sales Group Approaches End of Regulatory Progress Necessary for Approval

FOUNTAIN HILLS, Ariz. -- Ophthalmic International (www.ophthalmicinternational.com), a wholly owned subsidiary of Coronado Industries (OTCBB: CNDO) (www.coronadoindustries.com), said today that the Company had made marked progress toward completing registration of their Pneumatic Trabeculoplasty within the People's Republic of China.

Beijing Vision World Trading, Coronado's marketing partners in China, who have been working purposefully since being awarded an exclusive agreement in January of this year, recently informed Coronado Industries that they were approaching the end of the regulatory process to gain approval for "PNT" to be marketed in China.

Officers of Beijing Vision World had traveled to Arizona in August to meet with Coronado Industries management team, and view operations at their Fountain Hills facility. They outlined in great detail at that time the efforts made toward completing the process and the steps that were necessary in order to complete the process.

Coronado Industries was notified last week that the remaining process had advanced faster than originally planned and that the Chinese now anticipate market approval next quarter. To that end Beijing Visions officers will be traveling to the American Academy of Ophthalmology meeting next month in Nevada to meet with Coronado management to outline their marketing strategy and the rollout of "PNT" products in China.

In making the announcement today, G. Richard Smith, CEO of Coronado Industries, said he was delighted to be working with Beijing Vision World and the progress they had made in so short a period of time.

"We are so pleased with their diligence and their focus on the job in hand. They have meticulously documented all the efforts that they have made on our behalf in China, and their plan is so well organized and with such an attention to detail that we are confident of their ability to move forward in marketing our product in so vast a market. We have ample reason to believe we have made the right choice in having them represent us in a vital part of the world, which holds so much potential for us. It is a huge market and could soon produce a very substantial revenue stream," he said.

Ophthalmic International is focused on the development and commercialization of its patented procedure as a cost-effective alternative for the treatment of the most common types of glaucoma, which are open angle and pigmentary, as well as for the treatment of ocular hypertension.

For more information about Coronado Industries, please visit our website at www.coronadoindustries.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.